Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B

Abstract

Background

In the phase III Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (HELIOS-B), vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events and preserved functional capacity and quality of life. However, data in East Asian populations remain limited.

Objectives

The authors aimed to assess the efficacy and safety of vutrisiran in East Asian patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) enrolled in HELIOS-B.